Articles tagged "Immunosuppression"

2015 American Transplant Congress
2-Year Results on Renal Function and Safety for Everolimus plus Reduced-Exposure Calcineurin Inhibitor in Living Donor Kidney Transplant Recipients
T. Yagisawa,¹ N. Ishikawa,¹ N. Goto,² I. Nakajima,³ O. Kamisawa,⁴ S. Fuchinoue.³
¹Division of Renal and Transplantation, Jichi Medical University, Shimotsuke, Japan; ²Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ³Surgery, Kidney Center, Tokyo Women's University, Tokyo, Japan; ⁴Medical Division, Novartis Pharma K.K., Tokyo, Japan.
Purpose: The long-term effects of everolimus (EVR) with reduced cyclosporine (rCsA) exposure over 24 months on renal function and safety (viral infection) were assessed in…
2015 American Transplant Congress
T-Cell Immune Function Vs. Gene Expression Profiling for Heart Transplant Rejection
M. Luu, M. Kittleson, J. Patel, F. Liou, S. Siddiqui, L. Piponniau, A. Hage, D. Chang, L. Czer, A. Trento, J. Kobashigawa.
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Non-invasive immune monitoring of heart transplant (HTx) patients (pts) is increasing in use. The AlloMap® blood test has proven helpful in surveillance of cardiac…
2015 American Transplant Congress
Favorable Results of ABO Incompatible Renal Transplantation Without B Cell Targeted Therapy: Advantages and Disadvantages of Rituximab Pretreatment
M. Okada,¹ K. Futamura,¹ K. Itou,¹ T. Yamamoto,¹ T. Hiramitsu,¹ M. Tsujita,¹ N. Goto,¹ S. Narumi,¹ Y. Watarai,¹ A. Katayama,² K. Uchida,³ T. Kobayashi.⁴
¹Nagoya Daini Red Cross Hospital, Nagoya, Japan; ²Masuko Memorial Hospital, Nagoya, Japan; ³Aichi Medical University, Nagakute, Japan; ⁴Nagoya University School of Medicine, Nagoya, Japan.
INTRODUCTIONThe outcome of ABO-incompatible transplantation (ABO-I) has been reported to be comparable to that of ABO-identical/compatible transplantation (ABO-Id/C), which is considered to be due to…
2015 American Transplant Congress
Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients
S. Florman,¹ J. Medina Pestana,² M. Rial,³ L. Rostaing,⁴ D. Kuypers,⁵ F. Mühlbacher,⁶ M. Polinsky,⁷ U. Meier-Kriesche,⁷ J. Grinyó,⁸ A. Durrbach.⁹
¹Mt Sinai Med Ctr, NY; ²Hosp do Rim e Hipertensão, Sao Paulo, Brazil; ³Inst de Nefrologia, Buenos Aires, Argentina; ⁴Univ Hospital, Toulouse, France; ⁵Univ Hospital Leuven, Leuven, Belgium; ⁶Vienna Transplantation Ctr, Vienna, Austria; ⁷BMS, Lawrenceville; ⁸Univ Hosp Bellvitge, Barcelona, Spain; ⁹Univ Hosp of Bicêtre, Villejuif, France.
Background: At 3 and 5yrs post-transplant, BENEFIT-EXT showed a renal function benefit and consistent safety in belatacept (bela) treated pts vs cyclosporine (CsA). Final 7…
2015 American Transplant Congress
Effect of Intrapatient Variability and Mean Tacrolimus Levels in Renal Transplant Patients
D. Goodall, M. Willicombe, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
IntroductionNonadherence (NA) to immunosuppressive medication and adherence to immunosuppressive protocols is a potent risk factor for rejection and graft loss, which can be both patient…
2015 American Transplant Congress
Efficacy and Safety of Once-Daily Everolimus With Minimized Once-Daily Tacrolimus After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ A. Precisi,² D. Campani,³ F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Laboratory, University of Pisa Medical School Hospital, Pisa, Italy; ³Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background: The everolimus (EVR) pharmacokinetic profile allows for its once daily (OD) administration. We tested the efficacy and safety of a combination schedule of OD-EVR…
2015 American Transplant Congress
Emerging Application of Active Immune Targeted Delivery in Transplantation
M. Uehara,¹ A. Jamil,¹ M. McGrath,¹ Z. Solhjou,¹ N. Banouni,¹ S. Tullius,² C. Jianjun,³ R. Abdi.¹
¹Renal Division, Transplantation Research Center, Brigham and Women's Hospital, Harvard Medical Shcool, Boston, MA; ²Division of Transplant Surgery, Brigham and Women's Hospital, Boston, MA; ³Materials Science and Engineering, University of Illinois at Urbana-Champaign, Champaingn, IL.
Targeted nanodelivery has created enormous excitement as a transformative approach to deliver therapeutics to tissues of interest. In recent years, we have made significant progress…
2015 American Transplant Congress
Interleukin-17A Induced Human Mesenchymal Stem Cells Are Superior Modulators of Immunological Function
K. Sivanathan,^1,2,3 D. Rojas-Canales,^1,2 S. Grey,⁵ C. Hope,^1,2 R. Carroll,^1,4 S. Gronthos,^3,6 P. Coates.^1,2,3,4
¹Centre for Clinical and Experimental Transplantation, Royal Adelaide Hospital, Adelaide, South Australia, Australia; ²School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia; ³Centre for Stem Cell Research, Robinson Institute, University of Adelaide, Adelaide, South Australia, Australia; ⁴Central Northern Adelaide Renal Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, Australia; ⁵Transplantation Immunology Group, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia; ⁶Mesenchymal Stem Cell Laboratory, School of Medical Sciences, Faculty of Health Sciences, University of Adelaide, Adelaide, South Australia, Australia.
Interferon-gamma preactivated mesenchymal stem cells (MSC-γ) are highly immunosuppressive but immunogenic in vivo due to their inherent expression of major histocompatibility (MHC) molecules. We modified…
2015 American Transplant Congress
A Retrospective Review of a Renal Sparing Protocol in Orthotopic Liver Transplantation
B. Pierce,² J. Levitsky,^1,3 M. McLaughlin,² C. Richardson.²
¹Department of Medicine, Northwestern Medicine, Chicago, IL; ²Pharmacy, Northwestern Medicine, Chicago, IL; ³Hepatology, Northwestern Medicine, Chicago, IL.
Liver transplant recipients with pre-existing renal insufficiency are placed on a renal sparing protocol (RSP) consisting of delayed initiation of low-dose tacrolimus in addition to…
2015 American Transplant Congress
Toxicity Driven Conversion to Belatacept in Kidney Transplant Recipients
E. Cohen, W. Asch, R. Formica, E. Tichy.
Yale-New Haven Transplantation Center, New Haven, CT.
Purpose: Evaluate the result of conversion to belatacept from calcineurin inhibitor (CNI) or TOR inhibitor based regimens due to toxicities in kidney transplant recipients (KTR).Methods:…